\n<\/p>\n
The latest scientific findings have shed light on the role of the cannabinoid receptor in reducing negative ketamine side effects, confirm the risks of psychosis and cannabis use disorder among high potency cannabis consumers, and establish a new case of successful treatment of an autistic child with CBD.<\/p>\n
The antidepressant properties of ketamine have been demonstrated in both experimental and clinical studies, but the psychotomimetic side effects still limit its wider use as an antidepressant. The new study<\/a> founds that the motor hyperactivity induced by ketamine was reduced in CB1R male and female knockout and wild-type mice. However, genetic CB1R crossing out did not modify the antidepressant effect of ketamine in male mice submitted to the forced swimming tests. Scientists found it surprising that the pharmacological blockade of CB1R induced an antidepressant-like effect in both male and female mice, which was not further potentiated by ketamine.<\/p>\n These results support the hypothesis that CB1R mediates the psychostimulant side effects induced by ketamine, but not its antidepressant properties.<\/p>\n These findings are in line with previous research showing that co-administration of CBD and ketamine could be an attractive therapeutic strategy in treating depression; by promoting antidepressant effects while preventing the psycho-stimulant side effects of ketamine.<\/p>\n Ketamine and CBD: The Valuable Interaction<\/a><\/p>\n<\/blockquote>\n\n